BiotechTube
Artios Pharma

Artios Pharma

Cambridge, United Kingdom· Est.
artios.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $385M

Overview

Artios Pharma is a clinical-stage biotech positioned as a leader in the DNA Damage Response (DDR) field, building on the legacy of its founders who invented the blockbuster PARP inhibitor olaparib. The company is advancing a pipeline with first-in-class potential, including alnodesertib (ATR inhibitor) and ART6043 (Polθ inhibitor), supported by its proprietary DcoDeR discovery platform. With a seasoned leadership team and a strategy targeting high-unmet-need cancers, Artios aims to deliver transformative treatments through both monotherapy and combination regimens.

Oncology

Technology Platform

Proprietary DcoDeR platform designed to harness DDR biology for drug discovery, focusing on optimal drug combinations, biomarker insights, and patient stratification.

Funding History

4
Total raised:$385M
Series D$115M
Series C$153M
Series B$84M
Series A$33M

Opportunities

The growing need to overcome PARP inhibitor resistance creates a large addressable market for next-generation DDR inhibitors like ATR and Polθ inhibitors.
Fast Track Designation for ART6043 can accelerate its development and review in gBRCA-mutated breast cancer, a high-unmet-need population.
The proprietary DcoDeR platform provides a sustainable engine for identifying novel targets and rational combinations.

Risk Factors

Clinical failure in ongoing or future trials for its lead assets remains the primary risk.
The company operates in the highly competitive DDR space against larger, better-funded competitors.
As a private, pre-revenue company, it is dependent on raising capital to fund operations, which is subject to market conditions.

Competitive Landscape

Artios competes in the crowded but lucrative DDR field. For ATR inhibitors, competitors include Bayer (elimusertib), AstraZeneca (ceralasertib), and others. In Polθ inhibition, Artios claims its program is the most advanced clinically, but companies like Repare Therapeutics and IDEAYA Biosciences are also active. The company differentiates itself through its deep foundational expertise and platform approach to DDR biology.

More companies in Small Molecule Drugs →More companies in United Kingdom →